Human genetic variations in the 5HT2A receptor: A single nucleotide polymorphism identified with altered response to clozapine

Pharmacogenetics

Volumn 13, Issue 2, 2003, Pages 107-118

  Harvey, Layne ^a   Reid, Ronald E ^a   Ma, Caixia ^a   Knight, Peter J K ^a   Pfeifer, Tom A ^a   Grigliatti, Thomas A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

5HT2A receptor; Clozapine; Dose response; Loxapine; Serotonin; SNPs; Stable Sf9 transformants

Indexed keywords

CLOZAPINE; LOXAPINE; NEUROLEPTIC AGENT; SEROTONIN 2A RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ALLELE; ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CELL LINE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; GENETIC TRANSFORMATION; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; INSECT CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN VARIANT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; BLOTTING, WESTERN; CELL LINE; CLOZAPINE; DNA PRIMERS; FREE RADICAL SCAVENGERS; HUMANS; LOXAPINE; PLASMIDS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN ANTAGONISTS; SPODOPTERA; TRANSFORMATION, GENETIC; VARIATION (GENETICS);

INSECTA;

EID: 0242586109     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200302000-00007     Document Type: Article

References (47)

1. Kalow W. Pharmacogenetics, pharmacogenomics, and pharmacobiology. Clin Pharmacol Ther 2001; 70:1-4.
2. Kalow W. Pharmacogenetics in biological perspective. Pharmacol Rev 1997; 49:369-379.
3. Cargill M, Altschuler D, Ireland J, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999; 22:231-238.
4. Daley GQ, Cargill M. The heart SNPs a beat: polymorphisms in candidate genes for cardiovascular disease. Trends Cardiovasc Med 2001; 11:60-66.
5. Friddle C, Koskela R, Ranada A, et al. Full-genome scan for linkage in 50 families segregating the bipolar affective disease phenotype. Am J Hum Genet 2000; 66:205-215.
6. Glatt CE, Freimer NB. Association analysis of candidate genes for neuropsychiatric disease: the perpetual campaign. Trends Genet 2002; 18:307-312.
7. Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science 2002; 296:692-695.
8. Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 2000; 31:302-312.
9. Gaddum JH, Hameed KA. Drugs which antagonize 5-hydroxytryptamine. Br J Pharmacol 1954; 9:240-248.
10. Wolley DW, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA 1954; 40:228-231.
11. Meltzer HY, Matsubara S, Lee J-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1 and serotonin 2 pKi values. J Pharmacol Exp Ther 1989; 251:238-246.
12. Humphrey PP, Hartig P, Hoyer D. A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 1993; 14:233-236.
13. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994; 46:157-203.
14. Martin PEM, George CH, Castro C, et al. Assembly of chimeric connexinaequorin proteins into functional gap junction channels. J Biol Chem 1998; 273:1719-1726.
15. Williams J, McGuffin P, Nothen M, Owen MJ. Meta-analysis of association between the 5.HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia. Lancet 1997; 349:1221.
16. Williams J, Spurlock G, McGuffin P, et al. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet 1996; 347:1294-1296.
17. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18:63-101.
18. Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: A critical review. Am J Health-Syst Pharm 2000; 57:238-255.
19. Panchenko MP, Saxena K, Li Y, et al. Sites important for PLCbeta2 activation by the G protein betagamma subunit map to the sides of the beta propeller structure. J Biol Chem 1998; 273:28298-282304.
20. Nothen MM, Rietschel M, Erdman J, Oberlander H, Moller HJ, Nober D, Propping P. Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet 1995; 346:908-909.
21. Malhotra AK, Goldman D, Buchanan R, Breier A, Pickar D. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet 1996; 347:1830-1831.
22. Arranz MJ, Collier DA, Munro J, et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett 1996; 217:177-178.
23. Erdmann J, Shimron-Abarbanell D, Rietschel M, et al. Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 1996; 97:614-619.
24. Inayama Y, Yoneda H, Sakai T, et al. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet 1996; 67:103-105.
25. Ohara K, Nagai M, Tsukamoto T, et al. 5-HT2A receptor gene promoter polymorphism-1438G/A and mood disorders. Neuroreport 1998; 9:1139-1141.
26. Arranz MJ, Kerwin RW. Neurotransmitter-related genes and antipsychotic response: pharmacogenetics meets psychiatric treatment. Ann Med 2000; 32:128-133.
27. Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet 2000; 355:1615-1616.
28. Arranz MJ, Mancama D, Kerwin RW. Neurotransmitter receptor variants and their influence on antipsychotic treatment (Review). Int J Mol Med 2001; 7:27-30.
29. Arranz MJ, Munro J, Osborne S, Collier D, Kerwin RW. Applications of pharmacogenetics in psychiatry: personalisation of treatment. Expert Opin Pharmacother 2001; 2:537-542.
30. Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA, Kerwin RW. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 1998; 3:61-66.
31. Arranz MJ, Munro J, Owen MJ, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998; 32:93-99.
32. Sohdi MS, Arranz MJ, Curtis D, et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995; 7:169-172.
33. Malhotra AK, Goldman D, Ozaki N, et al. Clozapine response and the 5HT2C Cys23Ser polymorphism. Neuroreport 1996; 7:2100-2102.
34. Malhotra AK, Goldman D, Ozaki N, Breier A, Buchanan R, Pickar D. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry 1996; 153:1092-1094.
35. Kerwin R, Owen MJ. Genetics of novel therapeutic targets in schizophrenia. Br J Psychiatry 1999; 174(suppl 38):1-4.
36. Knight P, Pfeifer T, Grigliatti T. Patent PCT/CA01/015, filed 10.01.
37. Hegedus DD, Pfeifer TA, Hendry J, Theilmann DA, Grigliatti TA. A series of broad host range shuttle vectors for constitutive and inducible expression of heterologous proteins in insect cell lines. Gene 1998; 207:241-249.
38. Sankaran B, Osterhout J, Wu D, Smrcka AV. Identification of a structural element in phospholipase C beta2 that interacts with G protein betagamma subunits. J Biol Chem 1998; 273:7148-7154.
39. Roth BL, Choudhary MS, Khan N, Uluer AZ. High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. J Pharmacol Exp Ther 1997; 280:576-583.
40. Bading H, Hardingham GE, Johnson CM, Chawla S. Gene regulation by nuclear and cytoplasmic calcium signals. Biochem Biophys Res Commun 1997; 236:541-543.
41. Offermanns S, Simon MI. Galpha 15 and Galpha 16 couple a wide variety of receptors to phospholipase C. J Biol Chem 1995; 270:15175-15180.
42. Roth BL, Willins DL, Kristiansen K, Kroeze WK. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): Where structure meets function. Pharmacol Ther 1998; 79:231-257.
43. Lin CH, Tsai SJ, Yu YW, et al. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport 1999; 10:57-60.
44. Masellis M, Paterson HD, Badri F, Lieberman JA, Meltzer HY, Cavazzoni P, Kennedy JL, et al. Genetic variation of 5-HT2A receptor and response to clozapine. Lancet 1995; 346:1108.
45. Masellis M, Basile V, Meltzer HY, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998; 19:123-132.
46. Ozaki N, Manji H, Lubierman V, Lu SJ, Lappalainen J, Rosenthal NE, Goldman D, et al. A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization. J Neurochem 1997; 68:2186-2193.
47. Kehne JH, Ketteler H J, McCloskey TC, Sullivam CK, Dudley MW, Schmidt CJ, et al. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100 907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 1996; 277:968-981.